The Valley Desk

Case reportClinical lung cancerPublished

Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names University of Pennsylvania. Affiliation source

Publication record

Type
Case report
Venue
Clinical lung cancer
Published
Subject terms
Drug resistance; Non-small cell lung cancer; Tyrosine kinase inhibitor; Egfr Mutation; Met Mutation
PubMed ID
39743378
Added to directory
Source checked

Report a correction or request removal